Circulation. 2015 Jan 20;131(3):289-99. Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation. Gibson CC1, Zhu W1, Davis CT1, Bowman-Kirigin JA1, Chan AC1, Ling J1, Walker AE1, Goitre L1, Delle Monache S1, Retta SF1, Shiu YT1, Grossmann AH1, Thomas KR1, Donato AJ1, Lesniewski LA1, Whitehead KJ1, Li DY2. 1From the Program in […]Take a Tour
Int J Clin Pharmacol Res. 1985;5(1):59-62. Intrathecal orgotein. Lund-Olesen K. Abstract During the period 1971-78, 133 intrathecal injections of orgotein or superoxide dismutase have been given, mostly to patients with multiple sclerosis. Evaluation of the effect was deficient but the impression was that of improvement and 45% of the 58 patients with multiple sclerosis requested […]Take a Tour
Low Superoxide Dismutase and Catalase Activities and their Correlation with Malondialdehyde In Schizophrenic Patients
Indian J Clin Biochem. 2004 Jul;19(2):114-8. Superoxide Dismutase and Catalase Activities and their Correlation with Malondialdehyde in Schizophrenic Patients. Rukmini MS1, D’Souza B, D’Souza V. 1Department of Biochemistry, Centre for Basic Sciences, Kasturba Medical College, Bejai, 575 004 Mangalore, India. Abstract Free radical mediated pathological processes may have a role in schizophrenia. Free radicals (oxy […]Take a Tour
Antioxid Redox Signal. 2007 Oct;9(10):1731-43. Forum Review: Therapeutic and clinical applications of nitroxide compounds. Soule BP¹, Hyodo F, Matsumoto K, Simone NL, Cook JA, Krishna MC, Mitchell JB. ¹ Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland Abstract Nitroxide compounds have been used for many years as biophysical tools, but only […]Take a Tour
Neuropathology. 2009 Feb;29(1):1-8. Hayashi M¹. ¹Department of Clinical Neuropathology, Tokyo Metropolitan Institute for Neuroscience, Tokyo, Japan. Abstract Oxidative stress is one of the predisposing factors in adult neurological disorders. We have examined the involvement of oxidative stress in child-onset neurodegenerative disorders, and here we review the findings from our analysis. In cases of Cockayne syndrome, […]Take a Tour
Neuroprotective effects of TEMPOL in central and peripheral nervous system models of Parkinson’s disease.
Biochem Pharmacol. 2005 Nov 1;70(9):1371-81. Liang Q¹, Smith AD, Pan S, Tyurin VA, Kagan VE, Hastings TG, Schor NF. ¹Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA Abstract TEMPOL (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl) is a stable nitroxyl antioxidant. Previous studies have suggested that TEMPOL is protective in acute disorders thought to involve reactive oxygen species (ROS), such as […]Take a Tour
Tempol Moderately Extends Survival in a hSOD1G93A ALS Rat Model by Inhibiting Neuronal Cell Loss, Oxidative Damage and Levels of Non-Native hSOD1G93A Forms
PLoS One. 2013; 8(2): e55868. Linares E¹, Seixas LV, dos Prazeres JN, Ladd FV, Ladd AA, Coppi AA, Augusto O. ¹Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil. Abstract Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive dysfunction and death of motor neurons by mechanisms […]Take a Tour
Mitochondria-targeted antioxidants for treatment of Parkinson’s disease: Preclinical and clinical outcomes.
Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease Volume 1842, Issue 8, August 2014, pp 1282–1294 Misfolded Proteins, Mitochondrial Dysfunction, and Neurodegenerative Diseases Jin H1, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B, Kanthasamy AG 1 Parkinson’s Disorder Research Laboratory, Iowa Center for Advanced Neurotoxicology, Department of Biomedical Sciences, Iowa State University, Ames, IA […]Take a Tour